Anbio Biotechnology (NNNN) Stock AnalysisNNNNAnbio Biotechnology

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). It operates in the Healthcare sector.

Anbio Biotechnology (NNNN) is a good buy right now due to its recent 5-day price increase of 21.73% and a gross margin of 92.32% projected for Q2 2025, indicating strong profitability potential. The current price is $3.81, which is significantly lower than its historical SMA of $18.156, suggesting potential for recovery. However, the main risk is its year-to-date change of -87.08%, indicating high volatility and uncertainty in the stock's future performance.